Prognostic importance of plasminogen inhibitor-1 (PAI-1) in primary breast cancer;PROGNOSTISCHE BEDEUTUNG DES PLASMINOGENAKTIVATOR INHIBITOR-1 (PAI-1) BEIM PRIMAREN MAMMAKARZINOM

Geburtshilfe und Frauenheilkunde

Volumn 56, Issue 1, 1996, Pages 28-34

  Fersis, N ^a   Kaufmann, M ^a   Kramer, M D ^b   Wittmann, G ^a   Wallwiener, D ^a   Bastert, G ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CYTOSOL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; PROGNOSIS; PROTEIN DEGRADATION;

EID: 0030050122     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1023245     Document Type: Article

References (36)

1. Abel, U., J. Berger, H. Wiebelt: Critleel: An exploratory procedure for the evaluation of quantitative prognostic factors. Meths. Inform. 23 (1984) 154-156.
2. Andreasen, P. A., L. S. Nielsen, P. Kristensen, J. Grondahl-Hansen, L. Skriver, K. Dano: Plasminogen activator inhibitor from fibrosarkoma cells binds urokinase-type plasminogen activator, but not ist proenzyme. J. Biol. Chem. 261 (1986) 7651-7654.
3. Bastert, G.: Malignome der Mamma. In Schmidt-Matthiesen, H., G. Bastert (Hrg.): Klinik der Frauenheilkunde und Geburtshilfe Band 12: Spezielle gynäkologische Onkologie. 2. Auflage. Urban & Schwarzenberg, München, Wien, Baltimore 1989.
4. Blasi, F., M. P. Stopelli, M. V. Cubellis: The receptor for urokinase-plasminogenactivator. J. Cell Biochem. 32 (1986) 179-186.
5. Bloom, H. J., W. W. Richardson: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br. J. Cancer 9 (1957) 359-377.
6. Breimann, L., J. H. Fridman, R A. Olsen, C. J. Stone: Classification and Regression Trees Wadsworth, Belmont (1984).
7. Burin, P., G. Chavanel, J. M. Foidart, J. Andrè: Alterations of the basement membrane and connective tissue antigens in human metastatic lymph nodes. Int. J. Cancer 31 (1983) 719-726.
8. Clark, G. M., L. G. Dressler, M. A. Owens, G. Pounds, T. Oldaker, W. L. McGuire: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N. Engl. J. Med. 320 (1989) 627-633.
9. Camiolo, S M., G. Markus, M. S. Piver: Plasminogen activator contene of gynecological tumors and their metastases. Gynecol. Oncol. 26 (1987) 364-373
10. Cox, D. R.: Regression models and live-tables. J. R. Stat. Soc. (B) 34 (1972) 187-220.
11. Dano, K., P. A. Andreasen, J. Grondahl-Hansen, P. Christensen, L. S. Nielsen, L. Skriver: Plasminogen activator inhibitors, tissus degradation and cancer. Adv. Cancer Res. 44 (1985) 139-266.
12. Duffy, M. J : Do proteases play a role in cancer invasion and metastasis? Eur. J. Cancer Clin. Oncol. 23, No. 5 (1987) 583-589.
13. Duffy, M. J., P. O'Grady, D. Devaney, K. O'Siorain, J. Fennelly, H. J. Lijnen: Urokinase-Plasminogen activator, a marker for aggressive breast carcinomas. Cancer 62 (1988) 531-533
14. Ellis, V., T. C. Wun, N. Behrendt, E. Ronne, K. Dano: Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem. 265 (1990) 9904-9908.
15. Foekens, J. A. M. Schmitt, W. L. J. Van Putten, H. A. Peters, M. Bontenbal, F. Jänicke, J. G. M. Klijn: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 52 (1992) 6101 -6105.
16. Foekens, J. A., M. Schmitt, W. L. J. Van Putten, H. A. Peters, F. Jänicke, J. G. M. Klijn: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J. Clin. Oncol. 12 (1994) 1648-1658.
17. Foucré, D., C. Bouchet, K. Hacéne, N. Pourreau-Schneider, A. Gentile, P. M. Martin, A. Desplaces, J. Oglobine: Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br. J. Cancer 64 (1991) 929-932.
18. Graeff, H., F. Jänicke, M. Schmitt: Klinische und prognostische Bedeutung tumorassoziierter Proteasen in der gynäkologischen Onkologie. Geburtsh. u. Frauenheilk. 51 (1991) 89-100.
19. Graeff, H., N. Harbeck, L. Pache, O. Wilhelm, F. Jänicke, M. Schmitt: Prognostic impact and clinical relevance of tumor-associated proteases in breast cancer. Fibrinolysis 6 (1992) 45-53.
20. Grondahl-Hansen, J., J. Christensen, C. Rosenquist, N. Brünner, H. T Mouridsen, K. Dano, M. Blichert-Toft: High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53 (1993) 2513-2521.
21. Jänicke, F., M. Schmitt, H. Graeff: Clinical relevance of the urokinase-type and tissue type plasminogen activators and of their type 1 inhibitor in breast cancer. Seminars in Thrombosis and Hemostasis Vol. 17, No 3 (1991)
22. Jänicke, F., M. Schmitt, L. Pache, K. Ulm, N. Harbeck, H. Höfler, H. Graeff: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node negative breast cancer. Breast cancer Res. Treat. 24 (1993) 195-208.
23. Jänicke, F., L. Pache, M. Schmitt, K. Ulm, C. Thomssen, A. Prechtel, H. Graeff: Both the cytosols and detergent extracts are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator type 1. Cancer Res. 54 (1994) 2527-2530.
24. Kaplan, E. L., P. Meier: Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481.
25. Kaufmann, M., G. E. Feichter, A. Nhila, K. Klinga, U. Abel: Flow-zytometrische Parameter, Hormonrezeptoren und axillärer Lymphknotenstatus als Prognosefaktoren beim primären Mammakarzinom. Gehurtsh. u. Frauenheilk. 48 (1988) 705-709.
26. Kramer, M. D.: Proteasesysteme von Keratinozyten, T-Lymphozyten und Granulozyten in Physiologie und Pathophysiologie des Hautorgans. Habiltationsschrift, Universität Heidelberg (1991).
27. Lehmann, E. L.: Nonparametric statistical methods based on ranks. McGrawhill, San Francisco, California (1975).
28. Liotta, L. A., C. N. Rao, S. H. Barsky: Tumor invasion and the extracellular matrix. Lab. Invest. 49 (1983) 336-349.
29. Liotta, L. A., P. S. Steeg, W. G. Steuer-Stevenson. Cancer metastasis and angiogenesis. An imbalance of positive and negative regulation. Cell 64 (1991) 327-349.
30. Meissauer, A., M. D. Kramer, M. Hofmann, L. J. Erkell, E. Jakob, V. Schirrmacher, G. Brunner: Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells. Exp. Cell Res. 192 (1991) 453-459.
31. Mignatti, P., B. Rifkin: Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73 (1993) 161-190.
32. Ossowski, L., E. Reich: Antibodies to plasminogen activator inhibit tumor metastasis. Cell 35 (1983) 611-619.
33. Reilly, D., L. Christensen, M Duch, N. Nolan, M. J. Duffy, P. A. Andreasen: Type-1 plasminogen activator inhibitor in human breast carcinomas. Int. J. Cancer 50 (1992) 208-214.
34. Schmitt, M., F. Jänicke, H. Graeff: Tumor-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Blood Coagulation and Fibrinoiysis 1 (1990) 695-702.
35. Sumiyoshi, K., S. Baba, S. Sakagushi, T. Urano, Y. Tanaka, A. Tanaka: Increase in levels of plasminogen activator inhibitor in human breast cancer: Possible role in tumor progression and metastasis. Thromb. Res. 63 (1991) 59-71.
36. Sumiyoshi, K., K. Serizawa, T. Urano, Y. Tanaka, A. Tanaka, S. Baba: Plasminogen activator system in human breast cancer. Inter. J. Cancer 50 (1992) 345-348.